Retatrutide (TFA)

Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) . Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity[1].

Product Specifications

Product Name Alternative

LY3437943 (TFA)

UNSPSC

12352209

Target

GCGR; GLP Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/retatrutide-tfa.html

Purity

99.10

Solubility

DMSO : ≥ 100 mg/mL|H2O : 20 mg/mL (ultrasonic; adjust pH to 9 with NH3·H2O)

Smiles

[Retatrutide(TFA)]

Molecular Formula

C221H342N46O68.xC2HF3O2

Molecular Weight

4731.33 (free base)

References & Citations

[1]Tamer Coskun, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34 (9) :1234-1247.e9.